FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Washington,	D.C.	20549	
-------------	------	-------	--

OMB APPROVAL									
OMB Number: 3235-02									
Estimated average burden									
hours per response	e: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* WEATHERMAN ELIZABETH H				2. Issuer Name and Ticker or Trading Symbol Silk Road Medical Inc [ SILK ]								Check a	tionship of Reporting Pe all applicable) Director		ng Pei	rson(s) to Is			
(Last)	(F	(First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 04/17/2023								Office below	r (give title		Other (s below)	specify	
C/O SILK ROAD MEDICAL, INC. 1213 INNSBRUCK DRIVE				4. If Amendment, Date of Original Filed (Month/Day/Year)								ine)	'						
(Street) SUNNYVALE CA 94089														Form filed by More than One Reporting Person					
(City)	(5	State) (2	Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	, or B	enefic	ially C	Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day)			Execution Date,		3. 4. Securities Acquii Disposed Of (D) (In: 5)		red (A) o	ind So	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)						
					Code	v	Amount	(A) or (D) Pri		Tr	Transaction(s) (Instr. 3 and 4)				(111341. 4)				
Common Stock 04/17/2					2023		S <sup>(1)</sup>		5,000	D	\$41	.91	144,454			D			
		Tal	ble II -								osed of, o				vned	l			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		if any	emed ion Date, /Day/Year)	4. Transa Code (I 8)		5. Num of Derive Secur Acqui (A) or Dispo of (D) (Instr. and 5	ative rities ired osed	6. Date Expirati (Month/	ion Da		7. Title Amour Securi Underl Deriva Securi 3 and	nt of ties lying tive ty (Instr.	8. Price Deriva Securi (Instr.	ative ity	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

## **Explanation of Responses:**

1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on November 22, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

(D)

Date Exercisable

Expiration Date

## Remarks:

/s/Mhairi Jones, by power of attorney \*\* Signature of Reporting Person

of Shares

Title

04/17/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.